Visão geral da empresa
Aptevo Therapeutics Inc. operates as a clinical-stage research and development biotechnology company dedicated to the creation of immunotherapeutic candidates designed to treat various forms of cancer within the United States. The enterprise utilizes proprietary platforms, specifically ADAPTIR and ADAPTIR-FLEX, to generate therapeutic products that target oncological conditions, reflecting a focused R&D strategy typical of the biotechnology sector. This company functions within the broader Healthcare sector and the specific industry of Biotechnology, where success is measured by the ability to advance clinical trials and secure regulatory approvals for novel treatments. The company's current scale is defined by a market capitalization of $5.16M and an employee count of 33, figures that indicate a very early-stage, capital-intensive organization with minimal operational footprint. The negligible revenue base combined with a small market cap suggests the firm is in a pre-revenue phase where value is derived entirely from intellectual property and pipeline potential rather than current sales performance.
Saúde financeira
The company reports revenue (TTM) as N/A, a net income (TTM) of $-25,967,000, and an EBITDA of $-26,072,000, highlighting a significant gap between top-line activity and bottom-line profitability driven by substantial operating expenses. The absence of reported revenue alongside deep negative net income reveals a cost structure heavily weighted toward research, development, and administrative overhead before any commercial income is realized. Free cash flow stands at $-15,881,000, indicating that the company is consuming cash reserves to fund its clinical programs rather than generating liquidity from operations. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a standard characteristic for clinical-stage biotechs where costs exceed revenues and no profitable sales have occurred yet. The balance sheet holds $21.62M in cash against $4.63M in debt, resulting in a debt-to-equity ratio of 26.63, which implies a leveraged position relative to equity but reflects a cash-rich status typical for entities preparing for late-stage trials. The current ratio is 3.81, demonstrating robust short-term liquidity and the ability to cover current liabilities with current assets, providing a buffer for ongoing R&D expenditures. Return on Equity is -234.6% and Return on Assets is -76.9%, metrics that reveal management is currently burning capital to build future value rather than generating immediate returns on the invested shareholder base.
Avaliação de valorização
Trailing P/E (TTM) is listed as N/A while the Forward P/E is -0.23, a divergence that implies earnings are currently negative and the forward metric reflects an expectation of future profitability that has not yet materialized in financial statements. The price-to-book ratio is 0.25, indicating that the market values the company at significantly less than its net book value, suggesting a market discount often seen in speculative biotechnology assets with high uncertainty. The Price to Sales ratio is N/A and the EV/EBITDA is 0.45, where the latter low multiple suggests the enterprise value is minimal relative to its negative earnings, pointing to a high-risk valuation profile. The 52-week high is $504.00 and the 52-week low is $3.84, placing the current trading price in a context of extreme volatility and a wide range of price discovery. The beta value is 1.51, which signifies that the stock's price volatility is 51% higher than that of the broader market, reflecting the high sensitivity of biotechnology equities to clinical trial outcomes and sector sentiment.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both N/A, as the company has not yet achieved commercial sales necessary to calculate year-over-year expansion rates. Since earnings are negative and revenue is N/A, no meaningful growth rate can be established to compare against revenue expansion, implying the firm is in an investment phase rather than a growth phase. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning all available capital is reinvested into research and development rather than distributed to shareholders. Consequently, the overall growth and income profile is characterized by a total lack of current income generation, relying exclusively on external capital markets and internal cash reserves to fund future clinical milestones.